Autopsy report · NCT00378573

Multicenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by Bevacizumab Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Incidence of GI Perforation”

The sponsor’s own words in the registry.

Life of this trial

Registered 4 months before it started.
Ran for about 1 year 8 months before it stopped.
17 participants enrolled.
Results were posted on the registry 1 year 4 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Sanofi
Sponsor type: Industry
Conditions: Non-small Cell Lung Cancer
Interventions: docetaxel; gemcitabine; bevacizumab
Participants: 17
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.